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Abstract:  Background: Antipsychotic augmentation is an effective treatment intervention for Obsessive Compulsive   
Disorder (OCD) patients resistant to Selective Serotonin Reuptake Inhibitors (SSRI) agents. This pilot study was   
conducted to evaluate the effectiveness and tolerability of Aripiprazole for the augmentation of standard treatments in  
patients with resistant OCD. 
Methods: Twenty patients diagnosed with OCD according to DSM-IV TR criteria and having a history of resistance to 
standard pharmacological treatment were included in the study. Aripiprazole was added to ongoing SSRI or clomipramine 
treatment with a starting dose of 5 mg/day and titrated up to a maximum of 20 mg/day (mean dose 12.62 mg ± 4.25).  
Efficacy was assessed with the Yale-Brown obsessive compulsive scale (Y-BOCS) and the Clinical Global Improvement-
severity scale (CGI-S) at baseline and at week 12 of Aripiprazole augmentation. Side effects were monitored by the  
Udvalg for Kliniske Undersogelser (UKU) side effect rating scale. 
Results: All 20 subjects enrolled in our study completed the full 12-week course of treatment. A significant improvement 
over the 12-week study period was observed (paired t-test for mean Y-BOCS total score at week 12 as compared with 
baseline – all patients: t = 13.146, d.f. = 19, p= 0.0001). Aripiprazole was generally well tolerated and no changes were 
observed in vital signs. The most commonly observed side effects after the introduction of the augmenting agent included: 
akathysia, nausea/vomiting, hyperkinesia, tension/inner unrest, tremors, asthenia/lassitude/increased fatiguability.  
Conclusions: Although results of this pilot study are preliminary and require confirmation in randomized controlled trials, 
our experience suggested that Aripiprazole is effective and well-tolerated as an augmenting agent in patients with   
treatment resistant OCD.  
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INTRODUCTION 
Obsessive Compulsive Disorder (OCD) is a prevalent 
and disabling disorder with a lifespan prevalence   
approximately of 2,5% [1, 2]. The disorder follows a   
fluctuating course and only rarely resolves spontaneously 
[3].  
Most of the patients favourably respond to psychophar-
macological interventions with either selective serotonin 
reuptake inhibitors (SSRIs) or clomipramine. However, 
while these drugs are consistently superior to placebo, 40% 
to 60% of OCD patients fail to respond to an initial adequate 
trial and many times a substantial degree of residual symp-
tomathology may persist [4]. 
There have been many attempts to enhance the effects of 
SSRIs or clomipramine using several psychotropic com-
pounds as augmenting agents. Conventional antipsychotics 
have proved effective both in open and in double blind trials 
[5, 6]. Atypical antipsychotic have also been tested as add-on 
agents for treatment resistant OCD patients. Trials have been  
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succesfully conducted with risperidone [7-10], olanzapine 
[11-13], amisulpride [14] and quietiapine [15, 16]. 
Among these new drugs aripiprazole is also considered 
of interest because of its properties: it is an atypical   
antipsychotic with partial agonist activity at the dopamine 
D2 and serotonin 5HT1A receptors and antagonistic activity 
at the 5HT2-A receptors [17, 18]. 
Clinical efficacy of aripiprazole was observed for the 
treatment of comorbid obsessive compulsive symptoms in 
bipolar patients [19], schizophrenics [20] or in children with 
Tic Disorders [21]. In OCD patients resistant to conventional 
treatments, aripiprazole’s efficacy was first assessed as a 
monotherapy treatment in an open-label pilot trial [22]. 
However in these SSRI resistant OCD patients, the drug 
proved more effective as an augmenting strategy. This was 
observed in a series of case reports [23-26], and in two small 
open studies, one conducted on adult patients [27], and an-
other on adolescents [28]. 
The aim of this study was to provide confirmatory   
evidence for aripiprazole as a potential augmentation agent 
in the treatment of a larger sample of refractory OCD adult 
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study conducted in OCD patients with severe symptoms re-
sistant to standard pharmacological treatments.  
MATHERIALS AND METHODS 
Subjects  
The study was carried out at the Outpatient Center of the 
Department of Psychiatric Science and Psychological Medi-
cine of the SAPIENZA University of Rome during the pe-
riod February 2007 through October 2009. During this pe-
riod 28 consecutive patients who had received a diagnosis of 
OCD according to DSM-IV TR [29] criteria showed to be 
resistant to standard treatments. Of these 28 patients invited 
to participate, 20 (70%) were enrolled in the study. The most 
frequent reason reported by the 8 patients that refused to be 
enrolled in the study, was their concern for the potential ad-
verse effects of the treatment, due to the off-label use of 
aripiprazole. The key criterion for inclusion was treatment 
resistance to SSRIs or clomipramine, defined as no or inade-
quate response to previous treatment with at least two SSRIs 
or clomipramine, at an adequate dose and time (at least 12 
weeks) [30]. The second inclusion criterion was the severity 
of the obsessive-compulsive symptomatology as measured 
on the Y-BOCS [31]. Despite ongoing drug treatment, scores 
at baseline were of at least 16 or greater. In order to avoid 
possible methodological drawbacks, all diagnostic proce-
dures were carried out by three senior members of the re-
search team (RDC, MP, MC) with several years of practice 
and experience in clinical research. 
Key criteria for exclusion were the presence of a lifetime 
history of Bipolar Disorder, Schizophrenia, delirium or other 
psychotic disorders, personality disorders, a recent history of 
substance abuse or dependence, suicidal attempts, clinically 
significant medical disorder, laboratory abnormalities (endo-
crine, metabolic or ECG) and need for concurrent psychotro-
pic medications other than SSRIs, clomipramine or benzodi-
azepines at bedtime for sleep induction (if necessary).  
PROCEDURE AND ASSESSMENT 
Before entering, all subjects gave a written informed con-
sent, according to the procedures approved by the Hospital 
Committee, following full explanation of the aims of the 
study, of the off-label use of aripiprazole and of the avail-
ability of alternative, proven treatments for OCD. 
Treatment outcome was measured by the Y-BOCS total 
score and the Clinical Global Impressions Severity (CGI-S) 
[32]. Response was assessed by change in Y-BOCS total 
score from baseline to endpoint visit and the response crite-
ria were set as follows: “full response” 35% or greater reduc-
tion of Y-BOCS score, “partial response” greater than 25% 
but less than 35% Y-BOCS reduction, “non response” less 
than 25% Y-BOCS reduction”.  
Side effects were monitored with the UKU side effect 
rating scale [33]. Scales were administred at the end of the 
first visit (baseline evaluation). Subjects then returned for 
further follow-up visits, which were set at 3 weeks intervals. 
At the end of the 4
th visit (12
th week: endpoint) scales were 
newly administred. Vital signs and body weight were re-
corded both at baseline and at endpoint. All raters received 
specific training in the use of the study instruments. 
Unused study medication and the completed medication 
log were collected and reviewed at each visit to assess treat-
ment compliance. 
Aripiprazole, was administered in the morning and was 
added to ongoing SSRI or clomipramine with a starting dose 
of 5 mg/day in the morning. This dose was titrated up to a 
maximum of 20 mg/day, according to the patients clinical 
response and tolerability. Maximum dose reached was 20 
mg/day (mean dose 12,62 mg ± 4,25). 
Statistical Analysis 
We used a descriptive analysis to study the frequency 
distribution of all variables of interest, and the paired t-test to 
examine differences in scores on outcome measures at base-
line and follow-up assessments. SPSS for Windows, version 
13.0 was used for all analyses.  
RESULTS 
All of 20 subjects enrolled in our study completed the 
full 12-weeks course of treatment. The sample was com-
posed of 13 men and 7 female patients, all Caucasian and all 
yet treated for their OCD with a conventional therapy. Their 
ages ranged from 24 to 49 years (mean age 32,40 ± 6,38) 
with a mean duration of disorder of 12,5 years (± 6,72). All 
patients were on a standard anti OCD therapy: 14 patients 
were on clomipramine (mean dose 153,57 mg ± 33,40), 5 
patients were on paroxetine (mean dose 52 mg ± 8,36) and 1 
patient was on fluvoxamine (daily dose 300 mg). Sociode-
mographic and clinical characteristics of the twenty patients 
are shown in Table 1. 
Overall, a significant improvement in OCD symptoms 
was observed (Tables 2-3). On the basis of the Y-BOCS 
scores reduction response criterion, after the aripiprazole 
add-on 16 (80%) patients showed full response, 2 (10%) 
patients showed partial response and 2 (10%) patients were 
non responders. A significant reduction from baseline to 
endpoint was also showed by CGI-S scores. 
Aripiprazole was generally well tolerated and no changes 
were observed in vital signs. Baseline UKU scale scores 
were significantly reduced at endpoint (BL: 8,25±4,96, EP: 
6.25±4,65; p<.001). 
The most commonly observed side effects after the intro-
duction of the augmenting agent included akathysia (25%), 
nausea/vomiting (15%), hyperkinesia (15%), Tension/Inner 
unrest (10%), tremors and asthenia/lassitude/increased fati-
guability (10%). These symptoms never reached a score of 3 
on the UKU scale. Among other adverse effects, mainly ob-
served in patients under clomipramine, were dry mouth 
(35%), constipation (35%), erectile and ejaculative dysfunc-
tions (20%). None of these required drug discontinuation.  
DISCUSSION 
In this open-label study was considered a larger sample 
than previous studies conducted till now. Our results confirm 
that aripiprazole augmentation may be effective and well 
tolerated in patients with OCD refractory to standard treat-
ments. Aripiprazole Augmentation in OCD Resistant Patients  Clinical Practice & Epidemiology in Mental Health, 2011, Volume 7   109 
A full response was observed in 80% of the 20 patients 
treated in this study. Such rate of responders is higher than 
the rates observed by Connor [22] and Pessina [27]. Some 
methodological differences might account for this discrep-
ancy. With respect to the Connor study, since it was an 
aripiprazole monotherapy trial, higher response rates ob-
tained in our add-on study could depend upon this differ-
ence. In the Pessina study, only 8 out 12 of the enrolled pa-
tients completed the 12 weeks trial, while all of our 20 sub-
jects were completers. These differences could have influ-
enced the higher rate of responders found in our study. 
However, even if some of these differences could par-
tially explain our better results, our data are interesting, be-
cause we set the response threshold at a level of 35% reduc-
tion of the Y-BOCS score from baseline to endpoint to de-
fine a “full response”, while in the previous two studies this 
level was set at 30% and at 25% respectively. We cannot 
rule out anyhow the possibility that our pattern of findings 
may differ from previous studies depending on different 
OCD subtypes observed. 
High response rates however, have been reported also in 
several other studies when other antipsychotics were added 
as augmenting agents to standard treatments in patients with 
refractory OCD, such as 65% for haloperidol [5], 50%–
71.4% for quetiapine [15, 16], 50%–85% for risperidone 
[9,10] and 43.5%–70% for olanzapine [12, 13]. The highest 
response rate among these augmentation trials was observed 
in the amisulpride study (90%)[14]. Although the study de-
signs, definitions of resistance and response criteria were 
different, an explanation for the high rate of response to 
aripiprazole augmentation might lie in its pharmacodynamic 
profile. 
The role of the serotonergic system in the aetiology of 
OCD is well known, but not sufficiently to understand the 
disorder thoroughly. Indeed, a range of other neurochemical 
systems may be implicated in OCD, and the dopamine sys-
tem has been a particular focus of attention [34]. On the 
other hand, the increased dopaminergic activity may play a 
role in the pathophysiology of OCD and seems to point out 
that, among the properties of antipsychotic drugs, dopamine 
antagonism may contribute to enhance the efficacy of SSRIs 
in treatment resistant OCD patients.  
According to Positron Emission Tomography studies, 
atypical antipsychotics cause high levels of 5HT2 antago-
nism at low doses, whereas relatively high doses are required 
to produce significant dopamine D2 antagonism [35].  
In all the studies in which atypical antipsychotics were 
found to be effective augmenting agents for treatment resis-
tant OCD patients, significant results were reported at lower 
doses than those currently recommended for treatment of 
psychotic disorders [36]. This may indicate that the augmen-
tation of the ongoing anti OCD treatment obtained when 
these compounds are added, is mainly based on a modulation 
of the serotonin transmission rather than on a functional an-
tagonism on the dopamine system. Moreover, since low 
Table 1. Sociodemographic and Clinical Characteristics 
Patient  Sex  Age  Duration of OCD  AD Drug  AD Dose 
(mg/day) 
Aripiprazole (mg/day) 
1 F  41  5  Clomipramine  150  10 
2 F  34  8  Clomipramine  112,5  10 
3 M  37  15  Clomipramine  150  20 
4 M  39  19  Clomipramine  225  15 
5 M  35  15  Clomipramine  150  10 
6 M  30  14  Paroxetine  50  10 
7 M  27  6  Paroxetine  50  10 
8 M  31  10  Clomipramine  150  15 
9 F  30  10  Clomipramine  112,5  10 
10 M  30  16  Clomipramine  150  20 
11 F  24  3  Paroxetine  40  5 
12 M  38  18  Paroxetine  60  15 
13 M  38  25  Clomipramine  150  20 
14 F  26  3  Fluvoxamine  300  10 
15 M  49  22  Clomipramine  150  10 
16 F  32  13  Clomipramine  125  10 
17 M  37  24  Clomipramine    150  7,5 
18 M  27  8  Clomipramine  150  15 
19 M  24  6  Paroxetine  60  15 
20 F  29  10  Clomipramine  225  15 110     Clinical Practice & Epidemiology in Mental Health, 2011, Volume 7  Delle Chiaie et al. 
doses of antipsychotics mainly antagonize dopamine pre-
synaptic autoreceptor, this mechanism is more likely to in-
crease or modulate, rather than antagonize dopaminergic 
transmission. 
Furthermore, the high response rates we observed could 
depend on other pharmacologic properties of aripiprazole, 
such as its partial agonism at 5HT1a receptors. In fact the 
increase in synaptic 5HT caused by SSRIs activates feedback 
mechanisms mediated by 5HT-1a (cell body) and 5HT1b 
(terminal) autoreceptors, wich, respectively, reduce the firing 
in 5HT neurons and decrease the amount of 5HT released 
per action potential, resulting in attenuated 5HT neurotrans-
mission [37]. Partial agonism of aripiprazole at serotonin 
5HT-1 autoreceptors could modulate or reduce this mecha-
nism, resulting in an enhanced anti OCD efficacy of SSRIs. 
For these reasons, the unique pharmacological profile of 
aripiprazole based on its partial agonistic properties on do-
pamine transmission, could bring an advantage over other 
atypical antipsychotics in the treatment of refractory OCD 
and partially explain the results of our study.  
The present study has some limitations First, the lack of a 
placebo-controlled group which might mean that the results 
may reflect a natural improvement in OCD or a placebo ef-
fect. Second, the use of different antidepressants for standard 
treatment. Third, the small sample size and the open design 
of the study. As such the results are preliminary and require 
confirmation in a randomized controlled trial. 
To conclude, this study suggests that, as an augmenting 
agent, aripiprazole is effective and well tolerated in patients 
with treatment resistant OCD.  
Table 2. Outcome Measures 
Patient  BL 
Y-BOCS 
EP 
Y-BOCS 
Response  BL CGI-S  EP CGI-S  BL UKU Scale   EP UKU Scale 
1 26  12  Full  response  4 2 7 3 
2 24  16  Partial  response  5 2 4 7 
3 24  9  Full  response  5 2 8 5 
4 30  16  Full  response  6 3  14 10 
5 32  18  Full  response  6 2 9 4 
6 23  14  Full  response  4 2 4 2 
7 28  10  Full  response  5 3 0 2 
8 30  18  Full  response  6 2 9 4 
9 24  10  Full  response  4 2 5 2 
10 32  10  Full  response  5 2  12 7 
11 27  14  Full  response  5 2 0 0 
12 29  16  Full  response  5 3 3 5 
13 34  18  Full  response  6 2  11 7 
14 32  12  Full  response  5 3 5 3 
15 26  18  Partial  response  4 3  10 4 
16 28  22  Non  Response  5 2 8 5 
17 38  32  Non  Response  6 5  15 18 
18 31  10  Full  response  6 3  18 15 
19 28  10  Full  response  5 3 8 10 
20 32  18  Full  response  5 3  15 12 
CGI-S: Clinical Global Impression-Severity Scale; Y-BOCS: Yale-Brown Obsessive  
Compulsive Scale; BL: Baseline, EP: Endpoint. 
Table 3. Outcome Measures 
Y-BOCS BL  Y-BOCS EP  t df p 
28,99(±3,84) 15,55(±5,47) 13,146  19  .0001 
CGI-S BL  CGI-S EP       
5,1 (±0,71) 2,55(±0,75) 12,856  19  .0001 
Note. Paired t-tests are used for differences of means. P=by the two-tailed 
t-test. CGI-S: Clinical Global Impression-Severity Scale; Y-BOCS: Yale-Brown Obsessive  
Compulsive Scale; BL: Baseline, EP: Endpoint. Aripiprazole Augmentation in OCD Resistant Patients  Clinical Practice & Epidemiology in Mental Health, 2011, Volume 7   111 
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